Ozawa, Hiroko
Ueno, Shinji
Ohno-Tanaka, Akiko
Sakai, Takao
Hashiguchi, Masayuki
Shimizu, Mikiko
Fujinami, Kaoru
Ahn, Seong Joon
Kondo, Mineo
Browning, David J.
Shinoda, Kei
Yokogawa, Naoto
Funding for this research was provided by:
Tokyo Metropolitan goverment (the hydroxychloroquine retinopathy support program)
Article History
Received: 10 October 2020
Accepted: 26 March 2021
First Online: 20 May 2021
Conflicts of interest
: H. Ozawa, None; S. Ueno, Lecture fee (Novartis, TOMEY, Nidek, HOYA, Nikon, Sanofi), Collaboration research contract, Lecture Fee (Santen), Collaboration research contract (Astellas); A. O. Tanaka, None; T. Sakai, None; M. Hashiguchi, None; M. Shimizu, None; K. Fujinami, None; S. J. Ahn, Consultant fee (Novartis); M. Kondo, Financial support (AMO, Otsuka, Kowa, Santen, Senju, Alcon, Bayer, Pfizer, HOYA, Novartis), Consultant fee (Senju, Ono); D. J. Browning received the royalties on the book entitled Hydroxychloroquine and Chloroquine Retinopathy. 2014 published by Springer; K. Shinoda, Consultant fee (Astellas), Lecture fee (Bayer, Zeiss, HOYA, IQVIA, Kowa, Mitsubishi Tanabe, Novartis, Otsuka, Santen, Senju, TOMEY), Consultant fee, Lecture fee (Leica, Sanofi), Writing assistance, Consultant fee (Nitten); N. Yokogawa, Lecture fee (AbbVie, AYUMI, Bristol Myers Squibb, Chugai, Mitsubishi Tanabe, Takeda, UCB).